MedPath

Asparaginase Escherichia coli

Generic Name
Asparaginase Escherichia coli
Brand Names
Rylaze, Spectrila
Drug Type
Biotech
Chemical Formula
-
CAS Number
9015-68-3
Unique Ingredient Identifier
G4FQ3CKY5R
Background

Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exhibit antitumor actions in models of leukaemias . L-asparaginase of E. coli is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from E. coli works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death . For patients who develop hypersensitivity to E. coli-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated Asparaginase Erwinia chrysanthemi is recommended .

Indication

Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL)
Associated Therapies
-
Clinical Trials
Related News

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Phase 4
Completed
Conditions
Adult Acute Lymphocytic Leukemia
First Posted Date
2005-09-20
Last Posted Date
2023-03-20
Lead Sponsor
Goethe University
Target Recruit Count
225
Registration Number
NCT00199056
Locations
🇩🇪

University Hospital, Medical Dept. II, Frankfurt, Germany

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

First Posted Date
2005-09-16
Last Posted Date
2008-04-23
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
42
Registration Number
NCT00187122
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

First Posted Date
2005-09-15
Last Posted Date
2014-06-09
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
60
Registration Number
NCT00176462
Locations
🇺🇸

Jersey Shore University Medical Center, Neptune, New Jersey, United States

🇺🇸

Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Treatment of Acute Lymphoblastic Leukemia in Children

First Posted Date
2005-09-14
Last Posted Date
2013-04-25
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
498
Registration Number
NCT00165178
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Treatment of Childhood Acute Lymphoblastic Leukemia

Phase 3
Terminated
Conditions
Acute Lymphoblastic Leukemia
First Posted Date
2005-09-14
Last Posted Date
2007-12-28
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
491
Registration Number
NCT00165087
Locations
🇺🇸

Ochsner Clinic, New Orleans, Louisiana, United States

🇨🇦

McMaster University, Hamilton, Ontario, Canada

🇺🇸

Maine Medical Center, Lewiston, Maine, United States

and more 7 locations

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

First Posted Date
2005-08-29
Last Posted Date
2024-04-17
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
100
Registration Number
NCT00136435
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇨🇦

Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 9 locations

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2005-08-17
Last Posted Date
2008-11-14
Lead Sponsor
Japan Adult Leukemia Study Group
Target Recruit Count
120
Registration Number
NCT00131053
Locations
🇯🇵

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2005-08-17
Last Posted Date
2008-11-14
Lead Sponsor
Japan Adult Leukemia Study Group
Target Recruit Count
240
Registration Number
NCT00131027
Locations
🇯🇵

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2005-05-04
Last Posted Date
2015-03-25
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
79
Registration Number
NCT00109837
Locations
🇺🇸

Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States

🇺🇸

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

🇺🇸

Minor and James Medical, PLLC, Seattle, Washington, United States

and more 75 locations

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2004-12-09
Last Posted Date
2017-12-12
Lead Sponsor
Children's Oncology Group
Target Recruit Count
134
Registration Number
NCT00098839
Locations
🇺🇸

Indiana University Medical Center, Indianapolis, Indiana, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

and more 43 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy